A simple, non-invasive test utilizing urine and vaginal fluid samples has been developed by researchers to help rule out womb cancer in women experiencing postmenopausal bleeding, according to a study published in the journal Lancet Obstetrics, Gynaecology, & Women’s Health. The approach could transform care for thousands of patients annually by sparing lower-risk individuals from invasive procedures while fast-tracking high-risk cases for urgent investigation.
How the New Womb Cancer Test Works for Postmenopausal Bleeding
Every year, hundreds of thousands of women worldwide receive a womb cancer diagnosis. While bleeding after menopause triggers an urgent cancer referral, data shows that only about 5% to 10% of women reporting this symptom actually have an underlying malignancy, according to the study findings. Traditional diagnostic methods—such as internal ultrasound scans, womb lining biopsies, and hysteroscopy examinations using a camera passed directly into the womb—are invasive, uncomfortable, and costly for healthcare systems. Developed at the University of Manchester and Manchester University NHS foundation trust, the alternative screening method examines cellular material gathered from urine and vaginal fluid samples.
Clinical Trial Results and Diagnostic Accuracy
Researchers evaluated the screening method in a study involving 1,864 women across seven hospitals in north-west England. Before undergoing routine clinical checks, these patients provided both a urine sample and a vaginal fluid sample. Standard biopsies or surgeries subsequently confirmed that 5% of the participants—99 out of the 1,864 women—had womb cancer. When cytologists who were blind to the patients’ diagnoses analyzed the samples, they successfully identified 80 of the 99 cancer cases and correctly returned a negative result for 93% of the women who were free of the disease.
Did you know? Only about 5% to 10% of women who report postmenopausal bleeding have an underlying cancer, yet all currently face the same invasive and costly diagnostic pathway.
Expert Insights and Clinical Limitations
Study authors emphasize that the screening tool is not yet accurate enough to rule out cancer entirely on its own. Instead, it is intended to triage patients by fast-tracking those at the highest risk for immediate investigation while sparing lower-risk individuals from prompt invasive testing unless symptoms persist. Researchers also noted that the trial samples were assessed by highly trained specialist cytologists, meaning it remains uncertain whether identical accuracy can be replicated in standard clinical settings. Furthermore, the test has not yet been studied in women who lack symptoms.
“Bleeding after the menopause is understandably alarming for women because it can be a sign of cancer, but the vast majority of those investigated will not have the disease,” said Prof Emma Davidson of the University of Manchester and Manchester University NHS foundation trust. “Our study shows that a simple test using urine and vaginal samples could help identify the women most likely to have cancer while safely reassuring many others much earlier in the diagnostic pathway.”
Frequently Asked Questions
What triggers an urgent womb cancer referral?
Bleeding occurring after menopause is the primary symptom that triggers an urgent medical referral for suspected womb cancer.
What percentage of women with postmenopausal bleeding have cancer?
According to clinical data, only about 5% to 10% of women who report bleeding after menopause are found to have an underlying cancer.
What are the current diagnostic tests for womb cancer?
Current diagnostic assessments include internal ultrasound scans, biopsies of the womb lining, and hysteroscopy procedures where a camera is inserted into the womb.
Where was the new urine and vaginal fluid test developed?
The test was developed by researchers at the University of Manchester and Manchester University NHS foundation trust, with findings published in the journal Lancet Obstetrics, Gynaecology, & Women’s Health.
To stay informed on the latest medical breakthroughs and healthcare research updates, subscribe to our newsletter or explore our related health coverage.
Worth a look